🇺🇸 FDA
Patent

US 12168802

Methods of diagnosing and treating CD55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (CHAPLE), a newly identified orphan disease

granted A61KA61K38/12

Quick answer

US patent 12168802 (Methods of diagnosing and treating CD55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (CHAPLE), a newly identified orphan disease) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/12